Since DHE readily crosses the BBB, it has been reported to have minimal side effects and doses among cholinesterase inhibitors (Park et al., 1996; Park et al., 2000; Ahn et al., 2004), and in addition to the current findings, it might be a promising candidate for the drug development of AD. Here, BCHE is linked to Alzheimer disease.